Get the Stockscreener App
232.91
0.41%
-0.96
Pre-market:
232.70
-0.21
-0.09%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $232.91, with a volume of 7.61M.
It is down -0.41% in the last 24 hours and up +1.45% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$233.87
Open:
$233.54
24h Volume:
7.61M
Relative Volume:
1.35
Market Cap:
$411.45B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
175.74
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-0.14%
1M Performance:
+1.45%
6M Performance:
+25.42%
1Y Performance:
+39.83%
1-Day Range:
$230.36
$238.15
1-Week Range:
$229.23
$239.29
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
232.91 | 413.34B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,049.60 | 921.91B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.51 | 481.86B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
127.31 | 245.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
95.05 | 239.34B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie, Genmab's Epkinly gets FDA nod for pivotal lymphoma treatment - Crain's Chicago Business
Why Johnson & Johnson's Share Price Is Popping This Month - The Motley Fool
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - Business Wire
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell? - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Healthcare Rotation Underway: 3 Stocks Leading the Charge - MarketBeat
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 - sharewise.com
Approvals extend use of Roche, AbbVie drugs in lymphoma - pharmaphorum
Will AbbVie Inc. stock outperform Dow Jones2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
How higher bond yields impact AbbVie Inc. stock2025 Top Decliners & Weekly Top Gainers Alerts - newser.com
Glenmark 3.0 In The Making, Invigorated By IGI-AbbVie Deal - Citeline News & Insights
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Risk Summary & Daily Technical Forecast Reports - newser.com
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulenceJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - newser.com
Is AbbVie Inc. reversing from oversold territoryQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
How AbbVie Inc. stock trades before earningsJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
How geopolitical risks impact AbbVie Inc. (Common Stock) (4AB0) stock2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Will AbbVie Inc. stock announce special dividendJuly 2025 Outlook & AI Optimized Trade Strategies - newser.com
Why AbbVie Inc. (4AB) stock stays resilient2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
Is AbbVie Inc. (4AB) stock a buy before earnings resultsJuly 2025 Opening Moves & Fast Entry and Exit Trade Plans - newser.com
Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? - Yahoo Finance
AbbVie Gets FDA Approval for Epkinly Combo for Relapsed Follicular Lymphoma - MarketScreener
AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - Investing News Network
FDA approves AbbVie’s EPKINLY combination therapy for lymphoma By Investing.com - Investing.com Canada
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment - GuruFocus
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - WV News
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Tre - GuruFocus
AbbVie, Genmab win FDA label expansion for Epkinly (GMAB) - Seeking Alpha
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Analyst recommendations: Alphabet, Amazon, Microsoft, AbbVie, Comcast… - MarketScreener
How AbbVie Inc. stock performs in easing cycles2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET - TradingView
A Look Into AbbVie Inc's Price Over Earnings - Benzinga
AbbVie (ABBV) Gains Health Canada Approval for New Lupron Depot Dosage - GuruFocus
AbbVie Stock Falls 4% -- What Investors Need to Know - Finviz
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer - Investing News Network
Filmmaker helps AbbVie spread the word about leukaemia - pharmaphorum
Is AbbVie Inc. stock undervalued vs historical averagesEarnings Beat & Community Supported Trade Ideas - newser.com
Why AbbVie Inc. stock appears on watchlists2025 Market WrapUp & Daily Price Action Insights - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominance2025 Year in Review & Growth Oriented Trade Recommendations - newser.com
Analyzing AbbVie Inc. with risk reward ratio chartsWeekly Stock Summary & Daily Stock Trend Reports - newser.com
Will AbbVie Inc. stock attract more institutional investorsJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - Yahoo Finance
How reliable is AbbVie Inc. (4AB) stock dividend growthJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Can AbbVie Inc. stock withstand economic slowdown2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
AbbVie Inc 4AB Stock Analysis and ForecastMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Why AbbVie Inc. (4AB) stock stays on top picks2025 Institutional Moves & Long Hold Capital Preservation Plans - newser.com
How AbbVie Inc. stock performs in rising dollar environment2025 Big Picture & AI Powered Trade Plan Recommendations - newser.com
Will AbbVie Inc. stock beat EPS estimates2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer - Investing News Network
AbbVie (NYSE: ABBV) debuts Second Winds CLL film; YouTube, Documentary+ in Dec 2025 - Stock Titan
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):